Aurkin A

Aurkin A is an allosteric inhibitor for the interaction between Aurora A Kinase (also known also Aurka) and TPX2, through targeting the TPX2 binding sites with Kd of 3.77 μM. Aurkin A can disrupt polyploidy induced by Alisertib (HY-10971) and increase apoptosis of tumor cells. Aurkin A can be used in research on mitosis and cancer[1][2].

Product Specifications

CAS Number

[1534060-58-6]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; Aurora Kinase

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/aurkin-a.html

Purity

98.0

Smiles

O=C(C1=C2C=CC=C(F)C2=NC(C3=CC(Br)=CC=C3)=C1)O

Molecular Formula

C16H9BrFNO2

Molecular Weight

346.15

Precautions

H302, H315, H319

References & Citations

[1]Janeček M, et al., Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2. Sci Rep. 2016 Jun 24;6:28528. |[2]Conway PJ, et al. Aurkin-A, a TPX2-Aurora A small molecule inhibitor disrupts Alisertib-induced polyploidy in aggressive diffuse large B cell lymphoma. Neoplasia. 2024 Sep;55:101014.